Cover Image
市場調查報告書

人類微生物叢:在急速出現的市場中開啟新的領域

The Human Microbiome: Advancing New Frontiers in a Rapidly Emerging Market

出版商 Insight Pharma Reports 商品編碼 351308
出版日期 內容資訊 英文 136 Pages
訂單完成後即時交付
價格
Back to Top
人類微生物叢:在急速出現的市場中開啟新的領域 The Human Microbiome: Advancing New Frontiers in a Rapidly Emerging Market
出版日期: 2016年01月31日 內容資訊: 英文 136 Pages
簡介

人類微生物叢的研究開發領域是在生物科技產業中最被關注的領域之一。過去數年聚集著多的關心,微生物叢領域在基礎及應用生物醫學研究的雙方中如字面那樣被探求。

本報告提供人類微生物叢研究開發趨勢與商業性方面,目前交易活動概要,25家參與企業簡介等彙整資料。

摘要整理

第1章 簡介

第2章 歷史與發展

第3章 人類微生物叢研究

  • 文化
  • 系統生物學
  • 微生物生態學
  • 合成生物學和微生物叢工程 其他

第4章 人類微生物叢研究開發的商業性方面

  • 在微生物叢領域活躍的企業
    • AdvancingBio Inc.
    • AOBiome LLC
    • Assembly Biosciences, Inc.
    • AvidBiotics Corp.:
    • C3 Jian, Inc.
    • Diversigen, Inc.
    • Eligo Bioscience
    • Enterome Bioscience SA
    • Evelo Therapeutics
    • Evolve BioSystems Inc.
    • ExeGi Pharma LLC
    • Human Longevity, Inc.
    • Interface Diagnostics
    • Intrexon Corporation
    • MaaT Pharma
    • MetaboGen AB
    • Microbiome Therapeutics LLC
    • OpenBiome, Inc.
    • Pureflora, Inc.
    • Rebiotix Inc.
    • Seres Therapeutics
    • Symbiotic Health Inc.
    • Symbiotix Biotherapies, Inc.
    • Synlogic Therapeutics
    • Synthetic Biologics Inc
    • ViThera Pharmaceuticals Inc.
    • Xycrobe Therapeutics, Inc.
  • 交易活動

第5章 市場趨勢

第6章 觀察和結論

  • 微生物叢市場潛力
  • 合成生物學
  • 腸內毒素症與疾病
  • 實驗室的結果的一貫性
  • 未來的方向性

第7章 採訪原稿

圖表

目錄

The field of Human Microbiome research and development is apparently one of the most popular hubs of the biotechnology industry. While the Human Microbiome Project, MetaHIT and other huge studies of human microbiota, have garnered a lot of attention over that past few years, the microbiome space has literally exploded in terms of both basic and applied biomedical research.

This report focuses on biomedical aspects of research, development, and commercial endeavors in the human microbiome space. It includes essential background information, evolution of the field, advances in basic research, events in the emerging commercial market, deal activity, interviews with experts, and trends in microbiome research and commerce. Primary sources of information for this report include the scientific literature, discussions with experts, and an online survey of individuals working in this space.

This Report Covers:

  • Advances in Research on the Human Microbiome
  • Commercial Aspects of Microbiome Research and Development
  • Current Deal Activity
  • Over 25 Companies Profiled
  • Survey data from exclusive Insight Pharma Reports Survey

Interviews with:

  • Lee Jones, Founder CEO, Rebiotix
  • Brian Varnum, PhD, Chief Development Officer C3 Jian
  • Yanjiao Zhou, MD, PhD, Research Scientist, The Jackson Laboratory for Genomic Medicine
  • Dr Bernard Malfroy-Camine, President and CEO, ViThera Pharmaceuticals
  • Mark L. Heiman, Ph.D., FTOS, Vice President, Research and CSO, MicroBiome Therapeutics (formerly NuMe Health)
  • Larry Weiss, MD, Chief Medical Officer, AOBiome, LLC
  • Karen E. Nelson, PhD, President, J. Craig Venter Institute (JCVI), Head, Microbiome Program, Human Longevity Institute (HLI)
  • Sara Malcus, PhD, CEO, MetaboGen AB

Table of Contents

Executive Summary

  • History and Evolution
  • Advances in Research on the Human Microbiome
  • Commercial Activity
  • Trends and conclusions

CHAPTER - 1

  • Introduction
  • Scope and Structure of the Report

CHAPTER - 2

  • History and Evolution
  • Exhibit 2.1 PubMed citations for the search term ‘human microbiome'

CHAPTER - 3

  • Advances in Research on the Human Microbiome
  • Culture
  • Systems Biology
  • Microbial Ecology
  • Synthetic Biology and Microbiome Engineering
  • Diet
  • The Virome
  • Diagnostics
  • Infectious Disease
  • The microbiome in health and disease
  • The Gut-Brain Axis
  • Multiple Sclerosis
  • Colorectal cancer
  • The Microbiome at the Extremes of Life

CHAPTER - 4

  • Commercial Aspects of Microbiome Research and Development
  • Selected Companies Active in the Microbiome Space
  • Exhibit 4.1 Companies Active in the Microbiome Space
  • AdvancingBio Inc.
  • AOBiome LLC
  • Assembly Biosciences, Inc.:
  • AvidBiotics Corp.:
  • C3 Jian, Inc.
  • Diversigen, Inc.
  • Eligo Bioscience
  • Enterome Bioscience SA
  • Evelo Therapeutics
  • Evolve BioSystems Inc.
  • ExeGi Pharma LLC
  • Human Longevity, Inc.
  • Interface Diagnostics
  • Intrexon Corporation
  • MaaT Pharma
  • MetaboGen AB
  • Microbiome Therapeutics LLC
  • OpenBiome, Inc.
  • Pureflora, Inc.
  • Rebiotix Inc.
  • Seres Therapeutics
  • Symbiotic Health Inc.
  • Symbiotix Biotherapies, Inc.
  • Synlogic Therapeutics
  • Synthetic Biologics Inc
  • ViThera Pharmaceuticals Inc.
  • Xycrobe Therapeutics, Inc.
  • Deal Activity
  • Exhibit 4.2 Deals
  • 4D Pharma - The Microbiota Company and GT Biologics
  • 4D Pharma and The APC Microbiome Institute UCC Ireland
  • Ab-Biotics SA and Janssen Research and Development
  • Enterome and Abbvie
  • Enterome and Gustav Rouss
  • Evelo Therapeutics and University of Chicago
  • Intrexon Corporation and Oragenics Inc.
  • Intrexon Corporation and Synthetic Biologics, Inc.
  • Optibiotix and Venture Life
  • Second Genome and APC Microbiome Institute University College Cork
  • Second Genome and Evotec
  • Seres Health and Nestlé
  • Symbiotix and National Institute of Allergy and Infectious Diseases (NIAID)
  • Synlogic and a Global Pharmaceutical Partner
  • Vedanta Biosciences and Janssen Research and Development

CHAPTER - 5

  • Market Dynamics
  • Exhibit 5.1 Respondents' Subject Matter Category inMicrobiome R&D
  • Exhibit 5.2 Type of Organization Where Respondents Work
  • Exhibit 5.3 Further description of type of company where respondents work
  • Exhibit 5.4 Respondents' Position/Designation at the Workplace
  • Exhibit 5.5 Type of Work Currently Performed by Respondents
  • Exhibit 5.6 Type of Work Respondents Will Likely Perform in the Next Year
  • Exhibit 5.7 Respondents' Current Research Focus by Body Site/Niche
  • Exhibit 5.8 Respondents' Current Research Focus by Therapeutic Area
  • Exhibit 5.9 Respondents' Current Research Focus by Disease Condition
  • Exhibit 5.10 Respondents' Current or Future Research Focus by Product
  • Exhibit 5.11 Respondents' Expectation of Change in Their Organization's Microbiome Involvement in the Next Two Years
  • Exhibit 5.12 Respondents' Opinion Regarding Academic Participation in Developing New Concepts for Rx and/or Dx of Dysbiosis
  • Exhibit 5.13 Respondents' Level Agreement with Statement: Current Methods are Adequate for Quantitative Characterization
  • of the Microbiome for Personalized Medicine
  • Exhibit 5.14 Respondents' Level Agreement with Statement: Sufficient Information about the Composition and Function of Human Microbiomes
  • has been Gathered to Justify Translational R&D
  • Exhibit 5.15 Respondents' Current Research Work on Detecting Dysbiosis Uses the Following Techniques
  • Exhibit 5.16 Respondents' Opinion on the Potential of Microbiome R&D to Provide Major Contributions to Healthcare
  • Exhibit 5.17 Respondents' Level of Agreement with the Statement: "Recent Findings Relating the Microbiome to Health and Disease
  • Will Enable an Important New Generation of Therapies for a Number of Chronic Diseases."
  • Exhibit 5.18 Respondents' Level of Agreement With the Statement: "Recent Findings Relating the Microbiome to Health and Disease
  • Will Provide an Important New Generation of Measures to Maintain Good Health."
  • Exhibit 5.19 Respondents' Level of Agreement With the Statement: "It is Still Early Days for Translational Interventions Based on Microbiome R&D,
  • and More Years of Research are Necessary to Establish its Potential."
  • Exhibit 5.20 Respondents' Level of Agreement With the Statement: "Sequencing Technologies Will Remain Dominant Over Microarrays
  • for Most Microbiome Diagnostic Applications."
  • Exhibit 5.21 Respondents' Level of Agreement With the Statement: "Big Pharma Involvement in Microbiome-related R&D Will Increase Significantly
  • Over the Next Decade."
  • Exhibit 5.22 Respondents' Level of Agreement With the Statement: "We Can Expect a Flood of New Rationally Designed and/or
  • Personalized Biotherapeutics to Emerge During the Next Decade."

CHAPTER - 6

  • Observations and Conclusions
  • Microbiome Market Potential
  • Synthetic Biology
  • Dysbiosis and Disease - Establishing Causality Over Correlation
  • Consistency of Results Across Laboratories
  • Future Directions

CHAPTER - 7

  • Interview Transcripts
  • Lee Jones, Founder CEO, Rebiotix
  • Brian Varnum, PhD, Chief Development Officer C3 Jian
  • Yanjiao Zhou, MD, PhD, Research Scientist, The Jackson Laboratory for Genomic Medicine, Farmington CT
  • Dr Bernard Malfroy-Camine, President and CEO, ViThera Pharmaceuticals
  • Mark L. Heiman, Ph.D., FTOS, Vice President, Research and CSO, MicroBiome Therapeutics (formerly NuMe Health)
  • Larry Weiss, MD, Chief Medical Officer, AOBiome, LLC
  • Karen E. Nelson, PhD, President, J. Craig Venter Institute (JCVI), Head, Microbiome Program, Human Longevity Institute (HLI)
  • Sara Malcus, PhD, CEO, MetaboGen AB
  • References
  • About CHI

Tables and Figures

  • Exhibit 5.1: Respondents' Subject Matter Category in Microbiome R&D
  • Exhibit 5.2: Type of Organization Where Respondents Work
  • Exhibit 5.3: Further description of type of company where respondents work
  • Exhibit 5.4: Respondents' Position/Designation at the Workplace
  • Exhibit 5.5: Type of Work Currently Performed by Respondents
  • Exhibit 5.6: Type of Work Respondents Will Likely Perform in the Next Year
  • Exhibit 5.7: Respondents' Current Research Focus by Body Site/Niche
  • Exhibit 5.8: Respondents' Current Research Focus by Therapeutic Areas
  • Exhibit 5.9: Respondents' Current Research Focus by Disease Condition
  • Exhibit 5.10: Respondents' Current or Future Research Focus by Product
  • Exhibit 5.11: Respondents' Expectation of Change in Their Organization's Microbiome Involvement in the Next Two Years
  • Exhibit 5.12: Respondents' Opinion Regarding Academic Participation in Developing New Concepts for Rx and/or Dx of Dysbiosis
  • Exhibit 5.13: Respondents' Level Agreement with Statement: Current Methods are Adequate for Quantitative Characterization of the Microbiome for Personalized Medicine
  • Exhibit 5.14: Respondents' Level Agreement with Statement: Sufficient Information about the Composition and Function of Human Microbiomes has been Gathered to Justify Translational R&D
  • Exhibit 5.15: Respondents' Current Research Work on Detecting Dysbiosis Uses the Following Techniques
  • Exhibit 5.16: Respondents' Opinion on the Potential of Microbiome R&D to Provide Major Contributions to Healthcare
  • Exhibit 5.17: Respondents' Level of Agreement with the Statement: "Recent Findings Relating the Microbiome to Health and Disease Will Enable an Important New Generation of Therapies for a Number of Chronic Diseases."
  • Exhibit 5.18: Respondents' Level of Agreement With the Statement: "Recent Findings Relating the Microbiome to Health and Disease Will Provide an Important New Generation of Measures to Maintain Good Health."
  • Exhibit 5.19: Respondents' Level of Agreement With the Statement: "It is Still Early Days for Translational Interventions Based on Microbiome R&D, and More Years of Research are Necessary to Establish its Potential."
  • Exhibit 5.20: Respondents' Level of Agreement With the Statement: "Sequencing Technologies Will Remain Dominant Over Microarrays for Most Microbiome Diagnostic Applications."
  • Exhibit 5.21: Respondents' Level of Agreement With the Statement: "Big Pharma Involvement in Microbiome-related R&D Will Increase Significantly Over the Next Decade."
  • Exhibit 5.22: Respondents' Level of Agreement With the Statement: "We Can Expect a Flood of New Rationally Designed and/or Personalized Biotherapeutics to Emerge During the Next Decade."
Back to Top